Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1286 in Advanced Solid Tumors
NCT06685068Phase 2Terminated
- Sponsor
- Genmab
- Start
- Nov 2024
- Primary completion
- Mar 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GEN1286 in solid tumor, sponsored by Genmab. Primary endpoints: Number of Participants With Adverse Events and Number of Participants With Dose Limiting Toxicities at 21 days. Started Nov 2024; status: terminated.
02
Drugs
GEN1286
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06685068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06685068.